Crude proportions, crude ORs, and adjusted ORs for ≥3 pre-diagnostic GP consultations, by cancera
| Patient characteristics | All responders who saw GP at least once, n | Responders with ≥3 consultations, n (%) | Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
|---|---|---|---|---|---|---|
| Cancer diagnosis | ||||||
| Small intestine | 218 | 131 (60.1) | 5.18 (3.92 to 6.84) | 5.09 (3.85 to 6.73) | ||
| Multiple myeloma | 2052 | 969 (47.2) | 3.08 (2.77 to 3.42) | 3.08 (2.77 to 3.43) | ||
| Pancreatic | 1137 | 485 (42.7) | 2.56 (2.24 to 2.92) | 2.52 (2.21 to 2.89) | ||
| Liver | 451 | 167 (37.0) | 2.02 (1.65 to 2.47) | 1.96 (1.60 to 2.40) | ||
| Bone sarcoma | 196 | 81 (41.3) | 2.42 (1.81 to 3.24) | 1.89 (1.39 to 2.56) | ||
| Brain | 474 | 186 (39.2) | 2.22 (1.83 to 2.70) | 1.86 (1.53 to 2.26) | ||
| Stomach | 1828 | 623 (34.1) | 1.78 (1.58 to 2.00) | 1.86 (1.65 to 2.09) | ||
| Hodgkin lymphoma | 969 | 417 (43.0) | 2.60 (2.25 to 2.99) | 1.79 (1.54 to 2.08) | ||
| Colon | 8053 | 2640 (32.8) | 1.68 (1.55 to 1.81) | 1.71 (1.58 to 1.85) | ||
| Gallbladder | 66 | 23 (34.8) | 1.84 (1.10 to 3.06) | 1.70 (1.03 to 2.80) | ||
| Non-Hodgkin lymphoma | 5523 | 1844 (33.4) | 1.72 (1.59 to 1.87) | 1.65 (1.52 to 1.80) | ||
| Cancer of unknown primary | 3537 | 1189 (33.6) | 1.74 (1.59 to 1.91) | 1.63 (1.49 to 1.80) | ||
| Ureteric | 331 | 100 (30.2) | 1.49 (1.17 to 1.90) | 1.63 (1.28 to 2.08) | ||
| Lung | 6405 | 2068 (32.3) | 1.64 (1.51 to 1.78) | 1.63 (1.50 to 1.77) | ||
| All other | 2281 | 753 (33.0) | 1.70 (1.52 to 1.89) | 1.60 (1.43 to 1.78) | ||
| Mesothelioma | 641 | 180 (28.1) | 1.34 (1.12 to 1.61) | 1.49 (1.24 to 1.80) | ||
| Laryngeal | 667 | 198 (29.7) | 1.45 (1.22 to 1.73) | 1.49 (1.24 to 1.78) | ||
| Soft-tissue sarcoma | 508 | 162 (31.9) | 1.61 (1.32 to 1.96) | 1.46 (1.19 to 1.78) | ||
| Ovarian | 2717 | 913 (33.6) | 1.74 (1.57 to 1.93) | <0.0001 | 1.45 (1.31 to 1.61) | <0.0001 |
| Renal | 1436 | 431 (30.0) | 1.48 (1.30 to 1.68) | 1.43 (1.26 to 1.63) | ||
| Oropharyngeal | 1155 | 338 (29.3) | 1.42 (1.24 to 1.64) | 1.30 (1.13 to 1.50) | ||
| Leukaemia | 2043 | 582 (28.5) | 1.37 (1.22 to 1.54) | 1.29 (1.14 to 1.45) | ||
| Oesophageal | 2887 | 737 (25.5) | 1.18 (1.06 to 1.31) | 1.23 (1.11 to 1.37) | ||
| Anal | 495 | 133 (26.9) | 1.26 (1.03 to 1.56) | 1.14 (0.92 to 1.40) | ||
| Penile | 174 | 38 (21.8) | 0.96 (0.67 to 1.38) | 1.07 (0.74 to 1.53) | ||
| Prostate | 8538 | 1863 (21.8) | 0.96 (0.89 to 1.04) | 1.06 (0.97 to 1.15) | ||
| Rectal | 5616 | 1265 (22.5) | Ref | Ref | ||
| Bladder | 6837 | 1397 (20.4) | 0.88 (0.81 to 0.96) | 0.99 (0.90 to 1.07) | ||
| Cervical | 706 | 203 (28.8) | 1.39 (1.17 to 1.65) | 0.95 (0.79 to 1.14) | ||
| Vulval/vaginal | 405 | 95 (23.5) | 1.05 (0.83 to 1.34) | 0.93 (0.73 to 1.18) | ||
| Parotid | 140 | 32 (22.9) | 1.02 (0.68 to 1.52) | 0.89 (0.60 to 1.34) | ||
| Thyroid | 940 | 197 (21.0) | 0.91 (0.77 to 1.08) | 0.63 (0.53 to 0.76) | ||
| Oral | 567 | 94 (16.6) | 0.68 (0.54 to 0.86) | 0.61 (0.49 to 0.77) | ||
| Endometrial | 3255 | 549 (16.9) | 0.70 (0.62 to 0.78) | 0.59 (0.53 to 0.66) | ||
| Testicular | 665 | 96 (14.4) | 0.58 (0.46 to 0.73) | 0.42 (0.33 to 0.53) | ||
| Melanoma | 3470 | 289 (8.3) | 0.31 (0.27 to 0.36) | 0.29 (0.25 to 0.33) | ||
| Ductal carcinoma in situ | 650 | 36 (5.5) | 0.20 (0.14 to 0.28) | 0.15 (0.10 to 0.21) | ||
| Breast | 17 549 | 883 (5.0) | 0.18 (0.17 to 0.20) | 0.13 (0.12 to 0.15) | ||
| Sex | ||||||
| Male | 45 151 | 11 613 (25.7) | Ref | <0.0001 | Ref | <0.0001 |
| Female | 50 431 | 10 774 (21.4) | 0.78 (0.76 to 0.81) | 1.24 (1.19 to 1.29) | ||
| Age group, years | ||||||
| 16–24 | 536 | 231 (43.1) | 2.40 (2.02 to 2.85) | 2.12 (1.75 to 2.56) | ||
| 25–34 | 1754 | 508 (29.0) | 1.29 (1.16 to 1.44) | 1.82 (1.61 to 2.06) | ||
| 35–44 | 5277 | 1046 (19.8) | 0.78 (0.73 to 0.84) | 1.46 (1.34 to 1.58) | ||
| 45–54 | 13 113 | 2937 (22.4) | 0.91 (0.87 to 0.96) | 1.38 (1.31 to 1.46) | ||
| 55–64 | 22 789 | 5881 (25.8) | 1.10 (1.06 to 1.15) | 1.18 (1.14 to 1.23) | ||
| 65–74 | 30 517 | 7327 (24.0) | Ref | <0.0001 | Ref | <0.0001 |
| 75–84 | 18 442 | 3860 (20.9) | 0.84 (0.80 to 0.88) | 0.84 (0.81 to 0.88) | ||
| ≥85 | 3154 | 597 (18.9) | 0.74 (0.67 to 0.81) | 0.78 (0.71 to 0.86) | ||
| Ethnic group | ||||||
| White | 91 824 | 21 024 (22.9) | Ref | Ref | ||
| Mixed | 456 | 161 (35.3) | 1.84 (1.52 to 2.23) | 1.79 (1.44 to 2.23) | ||
| Asianb | 1662 | 611 (36.8) | 1.96 (1.77 to 2.17) | <0.0001 | 2.20 (1.96 to 2.46) | <0.0001 |
| Black | 1280 | 483 (37.7) | 2.04 (1.82 to 2.29) | 2.17 (1.91 to 2.47) | ||
| Chinese | 236 | 71 (30.1) | 1.45 (1.10 to 1.91) | 1.30 (0.96 to 1.76) | ||
| Other | 124 | 37 (29.8) | 1.43 (0.97 to 2.10) | 1.57 (1.02 to 2.43) | ||
| Deprivation groupc | ||||||
| Affluent | 22 351 | 4883 (21.8) | Ref | Ref | ||
| Deprivation group 2 | 22 644 | 5127 (22.6) | 1.05 (1.00 to 1.09) | 1.04 (0.99 to 1.09) | ||
| Deprivation group 3 | 20 446 | 4743 (23.2) | 1.08 (1.03 to 1.13) | <0.0001 | 1.05 (1.00 to 1.10) | <0.0001 |
| Deprivation group 4 | 16 868 | 4117 (24.4) | 1.16 (1.10 to 1.21) | 1.08 (1.03 to 1.14) | ||
| Deprived | 13 273 | 3517 (26.5) | 1.29 (1.23 to 1.36) | 1.16 (1.10 to 1.22) | ||
| Survey year | ||||||
| 2010 | 30 498 | 7211 (23.6) | Ref | Ref | ||
| 2013 | 32 608 | 7775 (23.8) | 1.01 (0.97 to 1.05) | 0.0035 | 1.02 (0.98 to 1.06) | 0.0409 |
| 2014 | 32 476 | 7401 (22.8) | 0.95 (0.92 to 0.99) | 0.97 (0.93 to 1.01) | ||
| Total | 95 582 | 22 387 (23.4) | ||||
↵a The table is sorted in descending order of adjusted odds ratios. Rarer cancers without prior published evidence are denoted in bold italics.
↵b The Asian group excludes Chinese, which was treated as a separate category in all three surveys.
↵c As classified by the Index of Multiple Deprivation. OR = odds ratio.